Nurix Therapeutics, Inc. (NRIX)

NASDAQ: NRIX · Real-Time Price · USD

23.60

-0.55 (-2.28%)

At close: Jul 29, 2026, 4:00 PM EDT

23.80

+0.20 (0.85%)

After-hours: Jul 29, 2026, 7:48 PM EDT

Nurix Therapeutics Income Statement

Financials in millions USD. Fiscal year is December - November.

Millions USD. Fiscal year is Dec - Nov.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May '26 May 31, 2026	Nov '25 Nov 30, 2025	Nov '24 Nov 30, 2024	Nov '23 Nov 30, 2023	Nov '22 Nov 30, 2022	Nov '21 Nov 30, 2021
Revenue	36.77	83.98	54.55	76.99	38.63	29.75
Revenue Growth	-58.40%	53.95%	-29.14%	99.31%	29.84%	66.95%
Gross Profit	36.77	83.98	54.55	76.99	38.63	29.75
Selling, General & Admin	57.01	52.74	45.94	42.9	38	31.2
Research & Development	340.93	316.9	221.63	189.15	184.5	116.43
Total Operating Expenses	397.95	369.65	267.58	232.05	222.49	147.64
Operating Income	-361.18	-285.67	-213.03	-155.06	-183.87	-117.89
Total Non-Operating Income (Expense)	19.56	21.97	19.73	11.12	3.51	0.82
Pretax Income	-341.62	-263.7	-193.3	-143.95	-180.36	-117.06
Provision for Income Taxes	-	0.76	0.27	-	-	0.13
Net Income	-341.62	-264.46	-193.57	-143.95	-180.36	-117.19
Net Income to Common	-341.35	-264.46	-193.57	-143.95	-180.36	-117.19
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	100	87	67	54	49	43
Shares Outstanding (Diluted)	100	87	67	54	49	43
Shares Change	25.66%	29.12%	23.52%	11.79%	13.32%	173.68%
EPS (Basic)	-3.45	-3.05	-2.88	-2.65	-3.71	-2.73
EPS (Diluted)	-3.45	-3.05	-2.88	-2.65	-3.71	-2.73
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May '26 May 31, 2026	Nov '25 Nov 30, 2025	Nov '24 Nov 30, 2024	Nov '23 Nov 30, 2023	Nov '22 Nov 30, 2022	Nov '21 Nov 30, 2021
Free Cash Flow	-60.1	-263.47	-182.14	-89.48	-172.05	-90.03
Free Cash Flow Growth	-	-	-	-	-	-
Free Cash Flow Per Share	-0.60	-3.04	-2.71	-1.65	-3.54	-2.10
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-982.37%	-340.16%	-390.52%	-201.41%	-476.01%	-396.25%
Profit Margin	-929.18%	-314.90%	-354.85%	-186.98%	-466.93%	-393.93%
FCF Margin	-163.45%	-313.73%	-333.91%	-116.23%	-445.42%	-302.61%
EBITDA	-350.49	-266.81	-196.6	-141.41	-173.06	-111.8
EBITDA Margin	-953.31%	-317.71%	-360.41%	-183.68%	-448.03%	-375.81%
EBIT	-361.18	-285.67	-213.03	-155.06	-183.87	-117.89
EBIT Margin	-982.37%	-340.16%	-390.52%	-201.41%	-476.01%	-396.25%
Effective Tax Rate	-	-0.29%	-0.14%	0.00%	0.00%	-0.11%

SEC Filings: 10-K · 10-Q